During the past decade, Medical Center Ophthalmology Associates conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 29 clinical trials were completed, i.e. on average, 49.2% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 21 clinical trials were completed. i.e. 80.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medical Center Ophthalmology Associates" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Aerie Pharmaceuticals" with 8 trials sponsored, "Allergan" with 7 trials sponsored, "Kodiak Sciences Inc" with 5 trials sponsored and "Jaeb Center for Health Research" with 5 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medical Center Ophthalmology Associates" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "Duke University" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Medical Center Ophthalmology Associates" are "Diabetic Macular Edema" (11 trials), "Macular Degeneration" (10 trials), "Ocular Hypertension" (7 trials), "Geographic Atrophy" (6 trials) and "Diabetic Retinopathy" (5 trials). Many other conditions were trialed in "Medical Center Ophthalmology Associates" in a lesser frequency.

Most popular intervention types in "Medical Center Ophthalmology Associates" are "Drug" (69 trials), "Other" (16 trials), "Device" (6 trials), "Biological" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Aflibercept" (8 trials), "Placebo" (7 trials), "Ranibizumab" (7 trials) and "KSI-301" (5 trials). Other intervention names were less common.

The vast majority of trials in "Medical Center Ophthalmology Associates" are 79 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Medical Center Ophthalmology Associates". undefined are not yet recruiting, 6 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 47 completed trials in Medical Center Ophthalmology Associates, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Medical Center Ophthalmology Associates, 5 "Phase 1" clinical trials were conducted, 36 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".